Education and research
Clark completed her Bachelor of Science (Honours Class 1) degree at the
Australian National University in 1978, under the supervision of Dr Ken Reed and Dr
Lynn Dalgarno (who along with Dr John Shine uncovered the
Shine-Dalgarno sequence). She earned a PhD (1982) in Biochemistry at the
University of Adelaide, by
mapping and
sequencing human
histone genes, under the supervision of Dr Julian Wells. During her postdoctoral years (1983-1988) at Biotechnology Australia, Clark led studies on the first
recombinant vaccine development in Australia and
eukaryotic gene expression of human
inhibin,
IL-3 and
GM-CSF. As Group Leader of the Gene Regulation Unit at the Kanematsu Laboratories,
Royal Prince Alfred Hospital from 1992 - 2000, Clark developed highly sensitive techniques that enabled
DNA methylation sequencing of single genes from small volumes (<100 cells) using
sodium bisulphite, which converts
cytosine residues to
uracil residues in
single-stranded DNA, under conditions that preserve
5-Methylcytosine. In 2000, Clark established the Epigenetics Group at the Sydney Cancer Centre, Royal Prince Alfred Hospital and led the unit until 2004. She went on to establish the Epigenetics Research Program in the Cancer Research Division and the moved Garvan Institute of Medical Research and was appointed the inaugural Head of the Genomics and Epigenetics Division in 2015. Clark has published over 650 manuscripts which contributed to the emergence of an entirely new discipline of cancer
epigenomics. == Recognition and awards ==
Selected publications
• Chen, W., Zeng, Y. C., Achinger-Kawecka, J., Campbell, E., Jones, A. K., Stewart, A. G., ... & Clark, S. J. (2024). Machine learning enables pan-cancer identification of mutational hotspots at persistent CTCF binding sites. Nucleic Acids Research, gkae530. https://doi.org/10.1093/nar/gkae530 • Chitty, J. L., Yam, M., Perryman, L., Parker, A. L., Skhinas, J. N., Setargew, Y. F., ... & Cox, T. R. (2023). A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer. Nature Cancer, 4(9), 1326-1344. https://doi.org/10.1038/s43018-023-00614-y • Pidsley, R., Zotenko, E., Peters, T. J., Lawrence, M. G., Risbridger, G. P., Molloy, P., ... & Clark, S. J. (2016). Critical evaluation of the Illumina MethylationEPIC BeadChip microarray for whole-genome DNA methylation profiling. Genome biology, 17, 1-17. https://doi.org/10.1186/s13059-016-1066-1 • Peters, T. J., Buckley, M. J., Statham, A. L., Pidsley, R., Samaras, K., V Lord, R., ... & Molloy, P. L. (2015). De novo identification of differentially methylated regions in the human genome. Epigenetics & chromatin, 8, 1-16. https://doi.org/10.1186/1756-8935-8-6 • Van Dijk, S. J., Molloy, P. L., Varinli, H., Morrison, J. L., & Muhlhausler, B. S. (2015). Epigenetics and human obesity. International journal of obesity, 39(1), 85-97. https://doi.org/10.1038/ijo.2014.34 • Wiklund, E. D., Bramsen, J. B., Hulf, T., Dyrskjøt, L., Ramanathan, R., Hansen, T. B., ... & Clark, S. J. (2011). Coordinated epigenetic repression of the miR‐200 family and miR‐205 in invasive bladder cancer. International journal of cancer, 128(6), 1327-1334. https://doi.org/10.1002/ijc.25461 • Susan, J. C., Harrison, J., Paul, C. L., & Frommer, M. (1994). High sensitivity mapping of methylated cytosines. Nucleic Acids Research, 22(15), 2990-2997. https://doi.org/10.1093/nar/22.15.2990 ==References ==